Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Multi-center, Randomized, Double-blind, Placebo-controlled Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Subjects With Manifestations of Plaque Psoriasis and Impaired Quality of Life

NCT03774875 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03774875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03774875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Multi-center, Randomized, Double-blind, Placebo-controlled Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Subjects With Manifestations of Plaque Psoriasis and Impaired Quality of Life
Lead sponsor
Amgen
Phase
Phase 4
Overall status
Completed
Start date
March 28, 2019
Completion date
November 3, 2021
Enrollment
277 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis